Please ensure Javascript is enabled for purposes of website accessibility

healthcare investing

FILE PHOTO: Futures-options traders work on the floor at the New York Stock Exchange's NYSE American (AMEX) in New York City, U.S., January 13, 2026. REUTERS/Brendan McDermid/File Photo
Jan 14, 2026

US biotech sector poised for 2026 rebound as IPO interest revives

Investors see a potential biotech rebound in 2026 as IPO activity, dealmaking and lower rates offset lingering policy risks.

YOUR NEWS.
YOUR INBOX.
DAILY.

By subscribing you agree to our Privacy Policy.